Effects of capsaicin on visceral smooth muscle: a valuable tool for sensory neurotransmitter identification. Eur J Pharmacol. 2004, 500(1-3): 143-57.

Pharmacological evaluation of alpha and beta human tachykinin NK(2) receptor splice variants expressed in CHO cells. Eur J Pharmacol. 2004, 499(3): 229-38.

The N-terminal of icatibant and bradykinin interact with the same Asp residues in the human B2 receptor. Eur J Pharmacol. 2004, 491(2-3): 121-5.

Spatial and temporal pattern of expression of interstitial collagenase, stromelysin/transin, gelatinase A, and TIMP-1 during experimental gastric ulcer healing. Digestion. 2004, 70(2): 127-38.

Oxidative degradation of cardiotoxic anticancer anthracyclines to phtha acids. Novel function of ferrylmyoglobin. J Biol Chem. 2004 279(7): 5088-99.

Cellular and human pharmacokinetics of brivudin, a new antiherpetic drug. Recent Res Devel. Drug Metabol Disposition. 2004, 2:1-11.

Evidence for a central mechanism of action of S-(+)-ketoprofen. Eur J Pharmacol. 2004 483(2-3): 241-248.

Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des. 2004 10(28): 3651-8

Small molecule antagonists of the tachykinin NK2 receptor. Mini Rev Med Chem. 2004, 4(3): 331-40.

Molecular recognition: the fragment approach in lead generation. Drug Discov Today. 2004, 9(5): 229-38.

Insertion of aspartic acid moiety into cyclic pseudopeptides: synthesis and biological characterization of potent antagonists for the human Tachykinin NK-2 receptors. J Med Chem 2004 47(27): 6935-47

Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrom. Br J Pharmacol. 2004, 141(8): 1249-63.

11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat. Bioorg Med Chem. 2004, 12(3): 603-11.

Bradykinin B2 and GPR100 receptors: a paradigm for receptor signal transduction pharmacology Br J Pharmacol. 2004, 143(8): 938-41.

Mutagenesis at the human tachkykinin NK(2) receptor to define the binding site of a novel class of antagonist. Eur J Pharmacol. 2004, 488(1-3): 61-9.

Site-directed mutagenesis at the human B2 receptor and molecular modelling to define the pharmacophore of non-peptide bradykinin receptor antagonists. Biochem Pharmacol. 2004, 67(4): 601-9.

CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival. Int J Cancer. 2004, 108(3): 390-8.

Hydrogen sulfide (H2S) stimulates capsaicin-sensitive primary afferent neurons in the rat urinary bladder. Br J Pharmacol. 2004, 142(1): 31-4.

Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. Trends Pharmacol Sci. 2004, 25(1): 1-3.

Tachykinins and tachykinin receptors: a growing family. Life Sci. 2004, 74(12): 1445-63.

Clot penetration and fibrin binding of amediplase, a chimeric plasminogen activator (K2 tu-PA). Thromb Haemost. 2004, 91(1): 52-60.

MEN 15658: a new promising anti-tumoral drug active on resistant tumor cells. Anticancer Drugs. 2004, 15(2): 151-6.

Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle. Neurogastroenterol Motil. 2004, 16(2): 167-73.

Development and evaluation of glyburide fast dissolving tablets using solid dispersion technique. Drug Dev Ind Pharm. 2004 30(5): 525-34.